Please assess the completion status of the following clinical trial:

Trial Title: Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of gynecologic malignancy~* No chemotherapy in the last 12 months~* Scheduled to receive Carboplatin (AUC\>=4) and Paclitaxel every three weeks~* ECOG performance status 0 or 1~* English speaking~* Willing and able to provide informed consent~* Laboratory values within protocol-defined parameters~* No vomiting in the 24 hours prior to initiating chemotherapy~* If childbearing potential exists, negative pregnancy test within 7 days prior to registration~Exclusion Criteria:~* Significant cognitive compromise~* History of CNS disease (e.g. brain metastases, seizure disorder, dementia)~* Current or recent (within 30 days) treatment with another antipsychotic agent (antidepressant medications are OK)~* Concurrent radiotherapy treatment~* Known hypersensitivity to olanzapine~* Known cardiac arrhythmia, uncontrolled congestive heart failure or acute myocardial infarction within the last six months~* History of diabetes mellitus on medication (insulin or oral glycemic agent)~* Alcohol abuse / chronic alcoholism~* History of closed angle glaucoma~* Current enrollment in other clinical trials

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Nk1-RA (Type: ACTIVE_COMPARATOR): Nk1-RA will be given on day 1 of each 3-week chemotherapy cycle, for up to 6 cycles.
- Olanzapine (Type: EXPERIMENTAL): Olanzapine will be given on days 1-4 of each 3-week chemotherapy cycle, for up to 6 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).